TY - JOUR
T1 - Consensus classification of posterior cortical atrophy
AU - Alzheimer's Association ISTAART Atypical Alzheimer's Disease and Associated Syndromes Professional Interest Area
AU - Crutch, Sebastian J
AU - Schott, Jonathan M
AU - Rabinovici, Gil D
AU - Murray, Melissa
AU - Snowden, Julie S
AU - van der Flier, Wiesje M
AU - Dickerson, Bradford C
AU - Vandenberghe, Rik
AU - Ahmed, Samrah
AU - Bak, Thomas H
AU - Boeve, Bradley F
AU - Butler, Christopher
AU - Cappa, Stefano F
AU - Ceccaldi, Mathieu
AU - de Souza, Leonardo Cruz
AU - Dubois, Bruno
AU - Felician, Olivier
AU - Galasko, Douglas
AU - Graff-Radford, Jonathan
AU - Graff-Radford, Neill R
AU - Hof, Patrick R
AU - Krolak-Salmon, Pierre
AU - Lehmann, Manja
AU - Magnin, Eloi
AU - Mendez, Mario F
AU - Nestor, Peter J
AU - Onyike, Chiadi U
AU - Pelak, Victoria S
AU - Pijnenburg, Yolande
AU - Primativo, Silvia
AU - Rossor, Martin N
AU - Ryan, Natalie S
AU - Scheltens, Philip
AU - Shakespeare, Timothy J
AU - Suárez González, Aida
AU - Tang-Wai, David F
AU - Yong, Keir X X
AU - Carrillo, Maria
AU - Fox, Nick C
N1 - Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2017/3/2
Y1 - 2017/3/2
N2 - INTRODUCTION: A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings.METHODS: Consensus statements about PCA were developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA.RESULTS: A three-level classification framework for PCA is described comprising both syndrome- and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD], prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum.DISCUSSION: There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work.
AB - INTRODUCTION: A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings.METHODS: Consensus statements about PCA were developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA.RESULTS: A three-level classification framework for PCA is described comprising both syndrome- and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD], prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum.DISCUSSION: There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work.
KW - posterior cortical atrophy
KW - Alzheimer’s disease
KW - clinico-radiological syndrome
KW - pathophysiology
KW - biomarker
U2 - 10.1016/j.jalz.2017.01.014
DO - 10.1016/j.jalz.2017.01.014
M3 - Article
C2 - 28259709
SN - 1552-5260
SP - 1
EP - 15
JO - Alzheimer's & Dementia: The Journal of the Alzheimer's Association
JF - Alzheimer's & Dementia: The Journal of the Alzheimer's Association
ER -